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Abstract 
Background: Nuclear factors of activated T-cells (NFATs) have been mainly characterized in the context of immune 
response regulation because, as transcription factors, they have the ability to induce gene transcription. NFAT proteins 
are found in several types of tumors, for instance, pancreatic carcinoma. The role of NFATs in carcinogenesis is regulat-
ing central genes in cell differentiation and cell growth. NFAT proteins are primarily located in cytoplasm and only 
transported to the cell nucleus after activation. Here, they interact with other transcription factors cooperating with 
NFAT proteins, thus influencing the selection and regulation of NFAT-controlled genes. To identify and characterize 
possible interaction partners of the transcription factor NFATc2 in pancreatic carcinoma cells PaTu 8988t.
Methods: NFATc2 expression and the mode of action of Ionomycin in the pancreatic tumor cell lines PaTu 8988t 
were shown with Western blotting and immunofluorescence tests. Potential partner proteins were verified by means 
of immunoprecipitation and binding partners, their physical interactions with DNA pull-down assays, siRNA technolo-
gies, and GST pull-down assays. Functional evidence was complemented by reporter–promoter analyses.
Results: NFATc2 and Sp1 are co-localized in cell nuclei and physically interact at the NFAT target sequence termed 
NFAT-responsive promotor construct. Sp1 increases the functional activity of its binding partner NFATc2. This interac-
tion is facilitated by Ionomycin in the early stimulation phase (up to 60 min).
Conclusions: Oncological therapy concepts are becoming more and more specific, aiming at the efficient modu-
lation of specific signal and transcription pathways. The oncogenic transcription partner Sp1 is important for the 
transcriptional and functional activity of NFATc2 in pancreatic carcinoma. The binding partners interact in cells. Further 
studies are necessary to identify the underlying mechanisms and establish future therapeutic options for treating this 
aggressive type of tumor.
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Background
Malignant tumors are one of the worst scourges of 
humanity. Approximately 8.2 million people died of car-
cinoma in the year 2012 alone, a figure the World Health 
Organization estimates to rise to 13 million over the next 
2  decades [1]. Pancreatic adenocarcinoma is one of the 
most aggressive types of malignant tumors in humans 
[2]. The main reasons for its unfavorable prognosis is the 
combination of rapid tumor growth, early-onset metasta-
sis, and the availability of so far only inadequate diagnos-
tic and therapeutic options [3]. The oncogenic potential 
of pancreatic tumor cells is triggered by the activation of 
oncogenic signal cascades and the altered regulation of 
important transcription factors [4]. Recent studies have 
indicated the importance of NFAT transcription factors 
in the carcinogenesis of pancreatic carcinoma [5].
The abbreviation NFAT stands for ‘nuclear factor of 
activated T-cells’. These factors are not only found in 
T-cells but also in other cells beyond the immune system, 
in which they regulate the expression of central genes 
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with regard to cell differentiation and cell growth [6]. 
Additionally, NFAT proteins are also expressed in neu-
ral tissue, endothelial cells, the myocardial muscle, blood 
vessels, chondrocytes, keratinocytes, adipocytes, as well 
as in pancreatic tumor cells [7, 8].
NFAT proteins are primarily located in cytoplasm and 
only transported into the cell nucleus after activation. 
The calcium–calcineurin-NFAT signaling pathway is 
activated by an influx of calcium into the cell that leads 
to the dephosphorylation of NFAT, which allows it to 
enter the cell nucleus, thus increasing its DNA-binding 
affinity [9]. NFAT proteins are reverted to their original 
deactivated state in cytoplasm by rephosphorylation and 
nuclear export receptors [10].
Promoters of many genes that are highly important 
in regulating vital cell functions, such as cell prolifera-
tion, cell differentiation, survival, or programmed cell 
death, have binding sites for NFAT proteins, which—
at least potentially—regulate these promoters at the 
expression level [11]. In fact, NFAT proteins may both 
stimulate and inhibit cell growth [12]. Such pluripo-
tent effects depend on the type and activation status 
of the cell. In this respect, partner proteins seem to be 
of special significance [13]. Partner proteins are tran-
scription factors cooperating with NFAT proteins and 
thus substantially influence the selection and regula-
tion of NFAT-controlled genes [14]. The present work 
is focused on NFATc2 because of its high expression 
intensity in pancreatic carcinoma [15]. Yet, the func-
tion and DNA-regulating characteristics of NFATc2 are 
still unknown.
This study aimed at identifying and characterizing 
possible interaction partners of the transcription factor 
NFATc2 in pancreatic tumor cells.
Methods
Cell lines
The human pancreatic adenocarcinoma cell lines PaTu 
8988t were obtained from H. P. Elsässer (Philipps Univer-
sity of Marburg, Germany) and maintained in Dulbecco’s 
modified Eagle’s medium (Sigma-Aldrich) supplemented 
with 10% fetal calf serum (FCS) (Sigma-Aldrich) and 
1% Normocyn (Amaxa biosystems). Cells were cultured 
at 37  °C in humidified  CO2 atmosphere (5%) and main-
tained in monolayer culture. Experiments were done 
with cells at ~70–80% confluence.
Antibodies and reagents
Ionomycin was purchased from Sigma-Aldrich. For 
immunoblotting, membranes were probed with antibod-
ies against NFATc2 (Santa cruz), Sp1 (Santa cruz), MEF 
2A (Upstate cell signaling solutions), Lamin B (Santa 
cruz), and ß-actin (Sigma-Aldrich).
Fluorescence microscopy
PaTu 8988t cells were grown on chambered cover-
slips, either left untreated or treated with 10% FCS, and 
subjected to transfection with the indicated plasmids 
(NFATc2-GFP). Cells were washed, fixed with 4% para-
formaldehyde, blocked, and probed with NFATc2 (Santa 
cruz) and Sp1 (Santa cruz) antibodies. Proteins of inter-
est were detected by means of fluorochrome-conjugated 
secondary antibodies (Invitrogene), and nuclei were 
counterstained with 4′6-diamino-2-phenylindole (DAPI). 
Cells were evaluated with a fluorescence microscope 
(Zeiss, Oberkochen, Germany).
Subcellular fractionation, co‑immunoprecipitation, 
and immunoblotting
For subcellular fractionation, cells were washed twice 
with cold DPBS and re-suspended in lysis buffer (12.5 mL 
1 M HEPES, ph 7.5, 7.5 mL 5 M NaCl, 1.25 mL 200 mM 
EGTA, 25 mL 100% Gycerin, 2.5 mL Triton X-100, 1.05 g 
NaF, 1.11  g  Na4P2O7 × 10  H2O) containing the protease 
inhibitors Orthovandat (Sigma aldrich), Leupeptin (Sigma 
aldrich), Benzamidin (Sigma aldrich), PMSF (Sigma 
aldrich), Aprotinin (Sigma aldrich). After sonification, cells 
were centrifuged at 13.000  rpm for 5  min, and superna-
tants were transferred to new cups and incubated on ice.
For co-immunoprecipitation, 500 μg of the lysates was 
immunoprecipitated with 4 µL of the indicated antibod-
ies and protein G or A agarose (Roche Diagnostics). The 
immunoprecipitates were subjected to immunoblotting.
For Western blotting, protein extracts were analyzed 
by SDS–PAGE and blotted onto nitrocellulose. Upon 
protein extraction and gel transfer, membranes were 
washed in TBS washing buffer and incubated with perox-
idase-conjugated secondary antibodies. Immunoreactive 
proteins were visualized by means of an enhanced chemi-
luminescence detection system (Western blotting detec-
tion reagent, GE healthcare). Membranes were probed 
with anti-NFATc2 (Santa Cruz), anti-Sp1 (Santa cruz) 
and anti-MEF 2A (Upstate cell signaling solutions). Anti-
Lamin B (Santa cruz) and anti-ß-actin (Sigma-Aldrich) 
antibodies were used as loading control.
DNA pull‑down assay
For DNA pull-down assay, 200  μg proteins per sample 
was incubated for 3  h with 10  μL of biotinylated dou-
ble-stranded oligonucleotides containing the GGAAA 
consensus NFAT binding sequence of the human inter-
leukin-2 promoter (5′-tctaaggaggaaaaactgtttcatg-3′ 
and its complementary strand) (Biomers.net GmbH). 
DNA–protein complexes were further incubated with 
60  µL streptavidin-agarose beads (Sigma-Aldrich) for 
1  h, washed twice with lysis buffer, and subjected to 
immunoblotting.
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Preparation of the recombinant GST‑NFAT proteins 
and GST pull‑down assay
Bacteriologically expressed GST fusion proteins were 
coded by pGEX plasmids. We used BL21 strains of 
Escherichia coli for amplification of the pGEX GST-
NFAT plasmid and protein extraction. The transformed 
colonies were inoculated with 5  mL of LB medium 
(Roth) and 5  µL of ampicillin (Sigma-Aldrich), and the 
culture was incubated at 37  °C on an orbital shaker for 
12–15 h (up to OD660 of 0.2–2.0). Expression of NFAT 
fusion proteins was induced by adding 0.75 mL of IPTG 
solution (AppliChem). Bacteria were lysed by sonifica-
tion, and we identified the produced proteins by means 
of SDS–polyacrylamide gel electrophoresis. For the 
actual assay, we incubated 100 µL of purified glutathione 
agarose beads (GE Healthcare) with 3 µg of bacteriologi-
cally expressed GST or GST-NFAT and total protein at 
4 °C for 15–18 h. After centrifugation and several wash 
cycles, samples were mixed with 30  µL of Laemmli 
puffer, heated up to 95  °C for 5  min, and analyzed by 
Western blotting.
Transient transfection, siRNA, and luciferase reporter assay
Cells were seeded in 12-well plates. For transient trans-
fection of expression constructs, PaTu 8988t cells were 
transfected 24 h after seeding at 70% density using Trans-
Fast (Promega) as a transfection reagent according to the 
manufacturer’s instructions. The promoter constructs 
cisNFAT-Luc were kindly provided by Stratagene Garden 
Grove, USA.
Luciferase activity was measured using the Lumat LB 
9501 (Berthold Technologies, Mannheim, Germany) 
luminometer and the dual Luciferase Reporter Assay 
System (Promega) according to the manufacturer’s 
instructions. Firefly luciferase values were normalized 
to Renilla luciferase activity and are shown as mean 
values ± SD.
For siRNA transfection, we obtained NFATc2 siRNA 
(5′-CCAUUAAACAGGAGCAGAAtt-3′), Sp1 siRNA (5′-G 
GUAGCUCUAAGUUUUGAUtt-3′), and the Silencer 
Negative Control from Ambion (applied biosystems). Cells 
were transfected for 24 h using the siLentFect lipid reagent 
(Biorad) according to the manufacturer’s protocol.
Results
NFATc2 becomes translocated into the cell nucleus in the 
presence of Ionomycin
Interaction between NFATc2 and potential partner pro-
teins in regulating transcription necessitates the reliable 
translocation of NFATc2 into the cell nucleus with the 
aid of a stimulant. Ionomycin is the stimulant of choice 
because influx of calcium into the cell activates the cal-
cium–calcineurin-NFAT signaling pathway that leads to 
the dephosphorylation of NFAT, allowing it to enter the 
cell nucleus, and thus increases its DNA-binding affin-
ity. Immunofluorescent images of untreated cells (Fig. 1a) 
showed the presence of NFATc2 in the entire cell. In con-
trast, when a serum-free medium was added, NFATc2 
was only present in cytoplasm. After 10-min stimulation 
with Ionomycin, NFATc2 was translocated into the cell 
nucleus. This translocation had its maximum at 30  min 
and was still present after 60 min. The overlap of nucleus 
staining with DAPI confirmed the location of NFATc2 in 
the cell nucleus after stimulation with Ionomycin. This 
Fig. 1 NFATc2 becomes translocated into the cell nucleus after stimulation with Ionomycin. Pancreatic tumor cells mixed with serum-free medium 
for 3 h were stimulated with 0.5 µM of Ionomycin for 0, 10, 30, and 60 min. Evidence is provided by means of NFATc2 antibodies in Western blot 
analysis (b) or by immunofluorescence (a). Cell nuclei (blue) are stained with DAPI and endogenous NFATc2 (red) with alexarot
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translocation by Ionomycin could also be proven at the 
protein level by means of Western blotting (Fig. 1b).
Endogenous expression of NFATc2 partner proteins 
described in the literature and their physical interaction 
during immunoprecipitation
We identified already established partner proteins of 
NFAT in PaTu 8988t pancreatic carcinoma cells. These 
partner proteins have already been described in the lit-
erature for other organ systems and additionally fulfill the 
following criteria:
1. calcium-dependent regulation, and
2. verified oncogenic effect in the organism.
The effect was proven at the protein level by means 
of Western blot analysis. Subsequently, we investi-
gated protein–protein interactions in  vivo by means of 
immunoprecipitation.
Figure 2a shows the strong expression of both NFATc2 
and its potential partner proteins Sp1 and MEF 2A. Row 
1 of Fig.  2b shows immunoprecipitation of NFATc2 in 
relation to the duration of the stimulation with Iono-
mycin. In contrast to serum-free cells that only precipi-
tated little NFATc2, stimulation with Ionomycin yielded 
a significantly more intense signal. When verifying the 
potential partner proteins Sp1 and MEF 2A (row 2 and 
3) expressed in pancreatic carcinoma cells, Sp1 could 
also be precipitated as a binding partner of NFATc2. The 
signal strength of Sp1 also significantly increased dur-
ing stimulation with Ionomycin. MEF 2A could not be 
proven as a potential binding partner. Row 4–6 show the 
input controls.
NFATc2 co‑localizes with Sp1 in the same immunocomplex
The possible co-localization of NFATc2 and Sp1 in cell 
nuclei was investigated by means of immunofluorescence 
(Fig.  3). In untreated cells, NFATc2-GFP was present in 
the entire cell. In contrast, when a serum-free medium 
was added, NFATc2 was only present in cytoplasm. After 
stimulation with Ionomycin for 10 and 30 min, NFATc2 
was translocated into the cell nucleus. Translocation was 
at its maximum after 60  min. Sp1 did not seem to be 
subject to any regulation by Ionomycin and was mainly 
observed in the cell nucleus.
The overlap of NFATc2-GFP with Sp1 indicated Ion-
omycin-induced co-localization of the two partner pro-
teins in cell nuclei that could be verified by the additional 
overlap of nucleus staining with DAPI.
Co‑immunoprecipitation of NFATc2 and Sp1 complexes 
of pancreatic tumor cells
Supplementary immunoprecipitation experiments were 
conducted to examine the physical interaction between 
NFATc2 and Sp1 induced by Ionomycin with regard to 
the time interval. Using an antibody against NFATc2, two 
bands could be detected reflecting the different phospho-
rylation stages of the protein (Fig. 4a). 10-min stimulation 
with Ionomycin led to significant signal amplification of 
the activated dephosphorylized NFATc2 protein that was 
still present after 60  min stimulation. The lower bands 
reflect binding Sp1. Similar to NFATc2, 10 min stimula-
tion with Ionomycin led to significant signal amplifica-
tion of Sp1 protein that decreased after 1 h.
As conclusion, Ionomycin may facilitate the inter-
action between NFATc2 and Sp1 at the early stage of 
stimulation.
Sp1 was immunoprecipitated in an analogous manner. 
Co-immunoprecipitated NFATc2 was verified by means 
of Western blot analysis (Fig. 4b). Stimulation with Ion-
omycin significantly increased precipitation of Sp1. Co-
immunoprecipitated NFATc2 was also found at each of 
the three time points of stimulation. After binding, inac-
tive NFATc2 (time point 0  min) changed to activated 
NFATc2 after 10  min, whereas only few active NFATc2 
proteins seemed to be binding to Sp1 after 60 min.
NFATc2 and Sp1 physically interact at the NFAT target 
sequence
Physical interactions between NFATc2 and Sp1 as well as 
their activity status in the DNA were identified by means 
Fig. 2 Endogenous expression of NFATc2 partner proteins described 
in the literature and their physical interaction during immunopre-
cipitation. Proteins were verified in Western blot analysis using the 
antibodies NFATc2, Sp1, and MEF 2A as well as the loading control 
ß-actin (a). NFATc2 including its interaction partner was subsequently 
extracted by means of immunoprecipitation (b)
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of DNA pull-down assays (Fig. 5a). The pancreatic tumor 
cell lines PaTu 8988t were stimulated with Ionomycin for 
a certain period of time. We also examined the binding 
of NFATc2 and Sp1 to the oligonucleotide sequence con-
taining the NFAT consensus binding sequence GGAAA. 
Stimulation with Ionomycin increased the DNA-bind-
ing affinity of NFATc2 that resulted in stronger NFATc2 
binding to the NFAT target sequence. The fact that Sp1 
could be co-precipitated as a physical interaction partner 
of NFATc2 indicates the joint binding of both proteins at 
the NFAT consensus sequence.
Apart from the 30 min stimulation with Ionomycin, 
endogenous expression of NFATc2 was inhibited by 
means of siRNA technology (Fig. 5b). We investigated the 
extent to which DNA interaction of the partner proteins 
could be prevented.
In analogy to Fig.  5a and the previous immunopre-
cipitation investigations (Fig.  4a, b), Fig.  5b shows that 
stimulation with Ionomycin increased promoter bind-
ing of NFATc2 and Sp1. Additional cell treatment with 
siRNA against NFATc2 decreased NFATc2-Sp1-DNA 
binding compared to siControl (row 1 and 2). The total 
cell lysate of the treated cells was directly applied to row 
3 in the Western blot analysis to confirm the functional-
ity of siRNA. Row 4 shows the endogenous expression of 
ß-actin as loading control.
Fig. 3 Co-localization of NFATc2 and the transcription factor Sp1. PaTu 8988t cells were transiently transfected with NFATc2-GFP. The cells either 
remained in serum containing medium or, after 24 h, serum was removed for 3 h, and the cells were stimulated with 0.5 µM of Ionomycin for 0, 10, 
30, or 60 min. The cells were fixed into paraformaldehyde and incubated with the Sp1 antibody. Cell nuclei (blue) are stained with DAPI, endog-
enous Sp1 (red) with alexarot, and NFATc2-GFP green
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NFATc2 and Sp1 directly interact in vitro in GST pull‑down 
assay
GST pull-down assays were used to answer the ques-
tion if the transcription factors Sp1 and NFATc2 physi-
cally interact in pancreatic tumor cells. We examined 
the binding of bacteriologically expressed GST-NFATc2 
to Sp1 that had been overexpressed in the pancreatic 
carcinoma cell lines PaTu 8988t by transfection. Bacte-
riologically expressed GST fusion proteins that did not 
physically interact with the transcription partners were 
used as control. As a direct physical interaction partner, 
Sp1 could be precipitated with GST-NFATc2 fusion pro-
teins by means of Western blot analysis (Fig. 6).
Functional interaction between NFATc2 and Sp1
The functional relevance of NFATc2 and Sp1 binding to 
promoters was investigated with the aid of reporter-pro-
moter analyses (Fig.  7). Here, we also transiently trans-
fected the artificial NFAT-responsive reporter-promoter 
construct cisNFAT-Luc, which exclusively shows three 
consecutive activated NFAT binding sites, with the effec-
tor plasmids NFATc2 or Sp1 into the pancreatic tumor 
cells. For analysis, the basal activity of the promoter con-
struct cisNFAT-Luc was normalized to the value of 100 
followed by evaluation of the influences of regulatory 
changes. Transfection of the cisNFAT-Luc promoters 
showed the basal activity of the cell (column 1). Equally 
Fig. 4 Co-immunoprecipitation of NFATc2 and Sp1 complexes of pancreatic tumor cells. After 3 h incubation with serum-free medium, the cells 
were stimulated with 0.5 µM of Ionomycin, harvested, and lysed at defined time points (0, 10, and 60 min). NFATc2 or Sp1 proteins were immuno-
precipitated by means of an antibody coupled to an agarose bead. Sp1 binding to NFATc2 (a) or NFATc2 binding to Sp1 (b) were analyzed by means 
of Western blotting
Fig. 5 Physical interaction at the NFAT target sequence. DNA oligonucleotide, which includes the NFAT consensus binding sequence GGAAA, 
was either incubated with the cell lysate of cells stimulated with Ionomycin or untreated cells (a) or transiently transfected with ‘Silencer Negative 
Control’—siRNA or NFATc2-specific siRNA oligonucleotide and also stimulated or not stimulated (b). Proteins binding to the biotin-marked oligonu-
cleotide sequence were subsequently precipitated with streptavidin. By means of the respective antibodies, NFATc2 and Sp1 were determined by 
Western blot analysis
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weak luciferase assay values were found after the co–
transfection of Sp1 (column 2). Transfection of NFATc2 
resulted in a 16-fold increase in luciferase activity in 
comparison to the basal expression of the promoter 
(column 3). Co–transfection of the transcription fac-
tors NFATc2 and Sp1 into the cell yielded a further six-
fold activation of the reporter construct in comparison to 
NFATc2 activity alone (column 4). Thus, Sp1 may signifi-
cantly increase the functional activity of NFATc2 binding 
to the promoter.
Discussion
Binding partners are crucial for the specificity of tran-
scription factors in cells. In recent years, numerous stud-
ies have shown that nuclear factors of activated T-cells 
(NFATs) are not only present in T-cells but also in cells 
beyond the immune system. As transcription factors, 
T–cells play an important role in inducing gene transfer 
[16], regulating and controlling numerous genes respon-
sible for cell proliferation, cell differentiation, survival, 
and apoptosis [6]. This way, NFAT proteins influence 
central effects in tumor biology, such as stimulating angi-
ogenesis by upregulation of VEGF [17], triggering the 
proliferation of tumor cells by upregulating c-myc [9], or 
promoting the migration of tumor cells by COX-2 [18].
The fact that all pluripotent effects depend on the 
type of cell and its activity status is remarkable. Partner 
proteins seem to be of particular importance in gene 
expression induced by NFATs [19]. Such proteins are 
Fig. 6 Direct interaction between NFATc2 and Sp1 in GST pull-down 
assay. Bacteriologically expressed GST and GST-NFATc2 as well as Sp1 
previously over-expressed in the pancreatic tumor cells were exam-
ined by means of GST pull-down assay; precipitates were determined 
by Western blot analysis
Fig. 7 Functional interaction between NFATc2 and Sp1 in luciferase assay. The artificial NFAT-responsive reporter-promotor construct cisNFAT-Luc 
and the effector plasmids NFATc2 or Sp1, or both, were transiently transfected into the pancreatic tumor cell lines PaTu 8988t, and relative luciferase 
activity was determined. In the evaluation, the basal activity of the promoter construct cisNFAT-Luc is normalized to the value 100 and the influ-
ences of the regulatory changes are indicated in x-fold increase or reduction of this control. The test repeated three times
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transcription factors that cooperate with NFAT proteins, 
thus influencing the selection and regulation of NFAT-
controlled genes [14]. However, little is yet known about 
these binding partners.
The probably most well-known binding partner of 
NFAT is the transcription factor AP-1 (activator pro-
tein 1) in lymphocytes [20, 21]. But also FOXP3, MEF 
2A, IRF4, and GATA have been identified. Together 
with NFAT, these transcription factors activate or 
repress important target genes necessary for T cell acti-
vation [14]. Several other transcription factors have 
been described in the context of other cell systems, for 
instance, EGR in neurons, CREB in the differentiation 
of osteoclasts [22], CCAAT/enhancer binding proteins 
(C/EBP) in hepatocytes [23], and Sp1 in keratinocytes 
[24]. Kao et  al. described the interaction of Sox10 with 
NFATc3 in glial cells that ultimately contribute to myeli-
nation by regulating the Krox20 protein [25].
Little evidence exists on the effect partner proteins of 
NFATc2 have on the oncogenic behavior of pancreatic 
tumor cells. Therefore, the current work is focused on 
characterizing the binding partners of NFATc2 in pan-
creatic tumor cells and their verification by different 
molecular biological methods. The stimulant of choice 
was Ionomycin to guarantee the reliable translocation of 
NFATc2 into the cell nucleus. Stimulation with Ionomy-
cin causes influx of calcium into the cell, activating the 
calcium–calcineurin-NFAT signaling pathway. This acti-
vation leads to the dephosphorylation of NFAT, which 
allows it to enter the cell nucleus, thus increasing its 
DNA-binding affinity [26]. The disadvantage of the stim-
ulus is its cell toxicity that rules out long-term experi-
ments. The mode of action of Ionomycin was proven by 
immunofluorescence as well as Western blot analysis.
First interaction experiments by means of immunopre-
cipitation showed binding of NFATc2 to the transcription 
factor Sp1. The family of Sp (specificity protein) tran-
scription factors belongs to the zinc finger proteins and 
is divided into two sub-groups: the Sp-like factors Sp1 to 
Sp8 and the KLF-like factors KLF1 to KLF16 [27].
Sp-like transcription factors are highly important in 
eukaryotic transcription processes. By regulating the 
expression of multiple genes, these factors are involved in 
many cellular functions, such as cell proliferation, apop-
tosis, and differentiation, as well as in neoplastic transfor-
mation [28, 29]. Each family member differs in its ability 
to control transcription and regulate cellular processes 
[30]. Depending on the promoter and binding partner, 
Sp-like transcription factors may either have an acti-
vating or an inhibiting effect. KLF13, for instance, acti-
vates the promoters of the Simian virus (SV 40) and of 
γ-Globin but inhibits the cytochrome P450 CYP1A1 [31].
Even if the specific physiological function of Sp 
proteins is not yet fully understood, knock-out stud-
ies on mice have shown the involvement of this fam-
ily of transcription factors in the development of tissue 
and organs. Sp protein expression is also assumed to 
be a critical factor in tumor development and growth 
as well as in metastasis [32]. Kumar and colleagues 
described increased expression and activity of Sp1 in 
epithelial carcinoma in comparison to benign tumors 
[33]. In 2001, Shi et  al. found over-expression of Sp1 
in pancreatic tumor cells compared to normal tissue 
[34]. Sp1 has also been identified as a mediator of TGF 
ß-induced tumor progression in pancreatic carcinoma 
[35].
The application of further techniques has shown the 
direct interaction of transcription factors in the same 
immunocomplex at the NFAT target sequence GGAAA. 
Sp1 increases the functional activity of NFATc2 at the 
NFAT-responsive promoter construct. Our immunofluo-
rescent investigations showed that, in pancreatic tumor 
cells, NFATc2 stimulated with Ionomycin becomes trans-
located into the cell nucleus, co-locating with the onco-
genic transcription factor Sp1.
Stimulating pancreatic tumor cells with Ionomy-
cin seems to promote binding of the two partner pro-
teins NFATc2 and Sp1. Immunoprecipitation studies 
have shown that mainly the respective partner is pre-
cipitated under stimulation. Notable are the different 
stages of phosphorylation of NFATc2. Activated dephos-
phorylized NFATc2 is able to increasingly bind Sp1. Vice 
versa, immunoprecipitation of Sp1 may lead to the co-
precipitation of both activated and deactivated dephos-
phorylized NFATc2. One possible explanation may be 
that the binding partners NFATc2 and Sp1 interact, com-
plex, and jointly regulate target genes in the DNA. Glyco-
gen synthase kinase-3 (GSK-3) or casein kinase 1 (CK1) 
limit this process in time by re-phosporylizing NFAT 
[10], thereby causing the NFATc2-Sp1 complex to lose its 
DNA-binding affinity.
It remains unclear, however, to what extent Sp1 as a 
binding partner of NFATc2 has a direct influence on 
the transcriptional and functional activity of DNA in 
pancreatic carcinoma. To answer this question, we con-
ducted DNA pull-down assays and luciferase assays. Our 
investigations showed that stimulation with Ionomycin 
increases DNA-binding of NFATc2 and co-precipitated 
Sp1. Furthermore, Sp1 increased the transactivation of 
the NFAT-responsive promoter construct.
The oncogenic transcription factor Sp1 plays an impor-
tant role in the transcriptional and functional activity of 
NFATc2 in pancreatic carcinoma, in which the binding 
partners interact in the cell.
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Conclusions
Modern treatment strategies of tumor diseases are 
directed at the efficient modulation of specific signaling 
and transcription pathways. In this context, VEGF anti-
bodies [36], tyrosine kinase inhibitors [37], or EGFR anti-
bodies have been discussed for the treatment of advanced 
pancreatic carcinoma [38]. Fundamental to identifying 
new therapeutic approaches is comprehensive knowledge 
about the carcinogenesis [39]. The carcinogenic process 
involves many proteins that may act as transcription fac-
tors or co-factors, or both, with significant influence on 
the regulation of target genes. Next to the transcription 
factors NFATc2 and Sp1, many other proteins interac-
tively influence transcription processes by regulating 
promoter activity as required and by controlling cell 
functions. Here, NFATc2 seems to have a key role in the 
progression of pancreatic carcinoma [5].
Many further studies are necessary to identify the 
underlying mechanisms. Identifying and characterizing 
central partner proteins in the carcinogenesis of pan-
creatic carcinoma will help establish new therapeutic 
options in the treatment of this aggressive type of tumor.
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